Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:14 am
Author: Getaka|Social: XLinkedIn

Lasa Supergenerics Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹10.15Undervalued by 70.59%vs CMP ₹5.95

P/E (110.0) × ROE (1.0%) × BV (₹11.20) × DY (2.00%)

₹14.13Undervalued by 137.48%vs CMP ₹5.95
MoS: +57.9% (Strong)Confidence: 53/100 (Moderate)Models: 5 Under, 1 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹6.6234%Under (+11.3%)
Net Asset ValueAssets₹11.1816%Under (+87.9%)
EV/EBITDAEnterprise₹27.3514%Under (+359.7%)
Dividend DiscountDividends₹2.5511%Over (-57.1%)
ROCE CapitalReturns₹19.7014%Under (+231.1%)
Revenue MultipleRevenue₹28.3512%Under (+376.5%)
Consensus (6 models)₹14.13100%Undervalued
Key Drivers: EPS CAGR -34.9% drags value — could be higher if earnings stabilize. | P/E of 110 makes PE-ROE unreliable — asset/earnings models are better benchmarks.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -34.9%

*Investments are subject to market risks

Investment Snapshot

36
Lasa Supergenerics Ltd scores 36/100 (Weak)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health38/100 · Weak
ROCE 1.0% WeakROE 1.0% WeakD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 1/5 years Inconsistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 53.7% Stable
Earnings Quality50/100 · Moderate
OPM stable around 3% Steady
Quarterly Momentum25/100 · Weak
Revenue (4Q): -49% YoY DecliningOPM: -34.1% (down 34.9% YoY) Margin pressure
Industry Rank15/100 · Weak
P/E 110.0 vs industry 64.9 Premium to peersROCE 1.0% vs industry 13.0% Below peersROE 1.0% vs industry 25.4% Below peers3Y sales CAGR: 1% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:14 am

Market Cap 29.8 Cr.
Current Price 5.95
Intrinsic Value₹14.13
High / Low 19.6/5.65
Stock P/E110
Book Value 11.2
Dividend Yield0.00 %
ROCE1.00 %
ROE1.01 %
Face Value 10.0
PEG Ratio-3.16

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Lasa Supergenerics Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lasa Supergenerics Ltd 29.8 Cr. 5.95 19.6/5.65110 11.20.00 %1.00 %1.01 % 10.0
Anupam Rasayan India Ltd 14,532 Cr. 1,276 1,407/68684.5 2810.06 %7.33 %3.32 % 10.0
Aether Industries Ltd 14,807 Cr. 1,116 1,250/72379.5 1740.00 %9.92 %7.49 % 10.0
Arvee Laboratories (India) Ltd 159 Cr. 144 291/12976.3 28.50.00 %9.58 %6.79 % 10.0
Neogen Chemicals Ltd 3,120 Cr. 1,183 1,797/96771.3 3140.08 %10.7 %7.36 % 10.0
Industry Average12,530.04 Cr712.4964.87182.870.55%12.98%25.40%6.41

All Competitor Stocks of Lasa Supergenerics Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 31.7035.3230.5624.3026.6622.8230.8439.3933.0839.1420.013.062.20
Expenses 34.1630.9826.5123.2525.6026.8129.0438.6032.8135.7320.517.062.95
Operating Profit -2.464.344.051.051.06-3.991.800.790.273.41-0.50-4.00-0.75
OPM % -7.76%12.29%13.25%4.32%3.98%-17.48%5.84%2.01%0.82%8.71%-2.50%-130.72%-34.09%
Other Income 0.86-18.970.000.080.00-8.760.001.958.91-21.52-20.440.010.02
Interest 0.430.410.370.560.440.560.871.240.470.110.030.120.11
Depreciation 3.094.172.652.682.682.662.792.812.803.901.571.571.57
Profit before tax -5.12-19.211.03-2.11-2.06-15.97-1.86-1.315.91-22.12-22.54-5.68-2.41
Tax % -3.91%-21.92%580.58%-99.05%-29.61%-4.20%46.77%146.56%7.11%-35.40%-6.30%10.04%5.81%
Net Profit -4.92-15.00-4.95-0.02-1.46-15.30-2.73-3.235.49-14.29-21.12-6.25-2.55
EPS in Rs -1.21-2.99-0.99-0.00-0.29-3.05-0.54-0.641.10-2.85-4.22-1.25-0.51

Last Updated: March 4, 2026, 2:16 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 8:16 pm

MetricMar 2016n n 1mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 019924417016720113713010414264
Expenses 015320215813715412013610213666
Operating Profit 0464111304716-626-2
OPM % 23%17%7%18%24%12%-5%2%4%-3%
Other Income 0-243000-8-18-9-11-42
Interest 0121188204230
Depreciation 0818191716151311129
Profit before tax 0215-16530-6-42-19-19-53
Tax % -10%19%-25%23%23%-13%-9%14%-24%
Net Profit 0212-12423-5-39-22-15-44
EPS in Rs 5.40-5.260.895.60-1.31-7.71-4.34-2.95-8.83
Dividend Payout % 0%0%0%0%4%-24%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)500.00%-200.00%133.33%475.00%-121.74%-680.00%43.59%31.82%
Change in YoY Net Profit Growth (%)0.00%-700.00%333.33%341.67%-596.74%-558.26%723.59%-11.77%

Lasa Supergenerics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-3%
3 Years:1%
TTM:26%
Compounded Profit Growth
10 Years:%
5 Years:-25%
3 Years:-28%
TTM:133%
Stock Price CAGR
10 Years:%
5 Years:-32%
3 Years:-38%
1 Year:-73%
Return on Equity
10 Years:%
5 Years:-1%
3 Years:-10%
Last Year:1%

Last Updated: September 5, 2025, 9:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:33 am

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.050.05232341415050505050
Reserves 07594821011181086847346
Borrowings 011610785481920222227
Other Liabilities 03763694229312432168
Total Liabilities 022828725823220820916415110272
Fixed Assets 01191701621521431371191106858
CWIP 030770055300
Investments 00000000000
Other Assets 0801109080656740393313
Total Assets 022828725823220820916415110272

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -0-3404114419-172-3
Cash from Investing Activity + -00-44-7-2-4-311-08
Cash from Financing Activity + -004-33-10-36-0-4-2-6
Net Cash Flow -0-30-0216-10-0-0
Free Cash Flow -0-5-629133512-1205
CFO/OP -6%103%397%46%87%73%273%96%-45%

Free Cash Flow

MonthMar 2016n n 1mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.00-70.00-66.00-74.00-18.0028.00-4.00-28.00-20.004.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 6463624527507134
Inventory Days 9390901015646489284
Days Payable 711021701304168326835
Cash Conversion Cycle 8751-18164228223753
Working Capital Days 15-1-52-133512-17-4437
ROCE %42%13%-4%7%17%1%-12%-6%-1%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%53.65%
FIIs 0.00%0.00%0.00%0.01%0.12%0.00%0.01%0.00%0.00%0.47%0.00%0.00%
Public 46.34%46.34%46.34%46.33%46.23%46.34%46.32%46.35%46.35%45.88%46.35%46.34%
No. of Shareholders 28,81828,03127,77027,16127,61527,21727,96827,27227,18828,11528,65628,120

Shareholding Pattern Chart

No. of Shareholders

Lasa Supergenerics Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) -2.95-4.34-7.71-1.305.60
Diluted EPS (Rs.) -2.95-4.34-7.71-1.305.60
Cash EPS (Rs.) -0.49-2.21-5.032.129.49
Book Value[Excl.RevalReserv]/Share (Rs.) 16.7119.3023.6136.5439.07
Book Value[Incl.RevalReserv]/Share (Rs.) 16.7119.3023.6136.5439.07
Dividend / Share (Rs.) 0.000.000.000.250.25
Revenue From Operations / Share (Rs.) 28.4320.8225.8633.7149.76
PBDIT / Share (Rs.) 2.250.45-0.953.8611.62
PBIT / Share (Rs.) -0.20-1.68-3.630.417.73
PBT / Share (Rs.) -3.87-3.81-8.44-1.537.25
Net Profit / Share (Rs.) -2.94-4.34-7.71-1.325.60
PBDIT Margin (%) 7.912.17-3.6911.4423.36
PBIT Margin (%) -0.71-8.05-14.051.2315.54
PBT Margin (%) -13.60-18.31-32.62-4.5214.57
Net Profit Margin (%) -10.35-20.82-29.80-3.9111.25
Return on Networth / Equity (%) -17.62-22.47-32.65-3.6114.33
Return on Capital Employeed (%) -1.21-8.24-15.031.0818.79
Return On Assets (%) -14.53-14.40-23.57-2.6910.95
Asset Turnover Ratio (%) 1.130.660.710.670.92
Current Ratio (X) 1.900.770.911.651.59
Quick Ratio (X) 0.460.380.591.391.16
Inventory Turnover Ratio (X) 6.544.818.676.134.69
Interest Coverage Ratio (X) 4.191.17-1.15389.3324.08
Interest Coverage Ratio (Post Tax) (X) 1.34-5.71-3.5062.8612.60
Enterprise Value (Cr.) 83.63108.5890.15152.41239.23
EV / Net Operating Revenue (X) 0.581.040.691.111.18
EV / EBITDA (X) 7.4247.93-18.829.715.06
MarketCap / Net Operating Revenue (X) 0.591.050.711.241.20
Price / BV (X) 1.011.140.781.141.53
Price / Net Operating Revenue (X) 0.591.050.711.241.20
EarningsYield -0.17-0.19-0.41-0.030.09

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Lasa Supergenerics Ltd. is a Public Limited Listed company incorporated on 11/11/2016 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24233MH2016PLC274202 and registration number is 274202. Currently Company is involved in the business activities of Manufacture of veterinary preparations. Company's Total Operating Revenue is Rs. 142.45 Cr. and Equity Capital is Rs. 50.10 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Chemicals - Speciality - OthersPlot No C-4, C-4/1, MIDC, Lote Parshuram Industrial Area, Ratnagiri Dist. Maharashtra 415722Contact not found
Management
NamePosition Held
Dr. Omkar Pravin HerlekarChairman & Managing Director
Mr. Prathamesh ChalkeWhole Time Director
Mr. Ketan Bhau SongalIndependent Director
Mr. Pravin Gadalya LachakeIndependent Director
Mr. Yogesh Hari UghadaIndependent Director
Mrs. Rekha Hemant WakhIndependent Director

FAQ

What is the intrinsic value of Lasa Supergenerics Ltd and is it undervalued?

As of 14 April 2026, Lasa Supergenerics Ltd's intrinsic value is ₹14.13, which is 137.48% higher than the current market price of ₹5.95, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (1.01 %), book value (₹11.2), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Lasa Supergenerics Ltd?

Lasa Supergenerics Ltd is trading at ₹5.95 as of 14 April 2026, with a FY2026-2027 high of ₹19.6 and low of ₹5.65. The stock is currently near its 52-week low. Market cap stands at ₹29.8 Cr..

How does Lasa Supergenerics Ltd's P/E ratio compare to its industry?

Lasa Supergenerics Ltd has a P/E ratio of 110, which is above the industry average of 64.87. The premium over industry average may reflect growth expectations or speculative interest.

Is Lasa Supergenerics Ltd financially healthy?

Key indicators for Lasa Supergenerics Ltd: ROCE of 1.00 % is on the lower side compared to the industry average of 12.98%; ROE of 1.01 % is below ideal levels (industry average: 25.40%). Dividend yield is 0.00 %.

Is Lasa Supergenerics Ltd profitable and how is the profit trend?

Lasa Supergenerics Ltd reported a net profit of ₹-15 Cr in Mar 2025 on revenue of ₹142 Cr. Compared to ₹-5 Cr in Mar 2022, the net profit shows a mixed trend.

Does Lasa Supergenerics Ltd pay dividends?

Lasa Supergenerics Ltd has a dividend yield of 0.00 % at the current price of ₹5.95. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Lasa Supergenerics Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports